We have collected information about Delivery Of Rnai for you. Follow the links to find out details on Delivery Of Rnai.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2977003/
Jun 11, 2010 · The site of action of siRNA therapeutics is the cytosol. The barriers to siRNA delivery are multiple and depend on the targeted organs and the administration routes. In general, locoregional delivery of siRNA has fewer barriers compared to systemic delivery.Author: Jie Wang, Ze Lu, M. Guillaume Wientjes, Jessie L.-S. Au
https://www.alliedacademies.org/articles/rethinking-delivery-viral-vectors-and-rna-interference-7646.html
More recently developed vector systems have excellent safety profiles as a result of systematic improvements in this key area. The time has come to re-consider viral vectors in order to overcome the complications and allow efficient, specific and well-tolerated delivery in RNAi applications.Author: Jens Kurreck
https://www.nature.com/articles/d41586-019-03071-9
Oct 16, 2019 · Delivery has been such a significant challenge that those working in the area of RNAi therapeutics might be forgiven for admitting defeat. And there’s …Author: Bianca Nogrady
https://www.nature.com/articles/nbt.3078
Nov 17, 2014 · Neutralizing the RNA phosphodiester backbone enables delivery of siRNA across cell membranes. RNA interference (RNAi) has great potential to treat human disease1,2,3. However, in …Author: Bryan R Meade, Khirud Gogoi, Alexander S Hamil, Caroline Palm-Apergi, Arjen van den Berg, Jonathan C...
https://www.sciencedirect.com/science/article/pii/S0168365914005677
2.8. RNAi delivery strategies employed in the current clinical pipeline. The evolution of the RNAi clinical pipeline reflects the aforementioned advantages of systemic over local RNAi delivery. Just 3 years following the discovery of RNAi occurring in mammalian cells , in 2004 the first RNAi therapeutics candidate entered clinical development ...Author: D. Haussecker
https://www.sciencedirect.com/science/article/pii/S1818087614000646
The currently developed siRNA delivery systems for cancer therapy can be divided into four categories: chemical modifications, lipid-based nanovectors, polymer-mediated delivery systems, conjugate delivery systems, and others (exosomes, RNAi-microsponges, oligonucleotide nanoparticles). 4.1. Chemical modifications of anti-cancer siRNAAuthor: Cong-fei Xu, Jun Wang
https://www.ncbi.nlm.nih.gov/pubmed/29243000
Effective delivery systems are essential to enable the full therapeutic potential of RNAi. An ideal nanocarrier not only addresses the challenges of delivering naked siRNA/miRNA, including its chemically unstable features, extracellular and intracellular barriers, and innate immune stimulation, but also offers "smart" targeted delivery.Author: Xiuhui Chen, Xiuhui Chen, Lingegowda S. Mangala, Cristian Rodriguez-Aguayo, Xianchao Kong, Gabriel L...
Advirna is developing innovative solutions for oligonucleotide delivery to cells ex-vivo and in-vivo. Our technology platform - self-deliverable RNAi technology (sdRNAi) allows efficient knockdown of genes in hard-to-transfect cell lines ex vivo and in vivo using RNAi interference. sdRNAi technology is based on the deep chemical modification of siRNAs and allows efficient delivery of RNAi into ...
https://www.alnylam.com/2019/06/21/new-rnai-platform-advances-including-oral-route-of-administration-and-cns-and-ocular-delivery/
Jun 21, 2019 · We presented new advances in our RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs (siRNAs) directed to a liver target. The results were presented at the 3rd International Conference on the Long and the Short of Non-Coding RNAs, held...
Searching for Delivery Of Rnai?
You can just click the links above. The data is collected for you.
